# Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

> **NCT01802879** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT01802879
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-24
- **Primary completion:** 2018-11-19
- **Final completion:** 2018-11-19
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802879, "Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01802879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*